ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0046

Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts

Hanna Johnsson1, John Cole1, Stefan Siebert1, Iain McInnes2 and Gerard Graham1, 1University of Glasgow, Glasgow, United Kingdom, 2University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom

Meeting: ACR Convergence 2021

Keywords: immunology, Psoriatic arthritis, skin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Spondyloarthritis Including PsA – Basic Science Poster (0046–0068)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Up to 30% of patients with psoriasis develop psoriatic arthritis (PsA). The traditional assumption is that the skin disease is the same in both conditions, although a previous proteomic analysis found differences[1]. The aim of this project was to investigate and compare the skin transcriptome in PsA and psoriasis.

Methods: Full thickness skin biopsies were obtained from healthy controls (HC) and paired lesional and uninvolved skin from patients with PsA. Libraries for bulk RNA sequencing were prepared from polyA selected RNA and sequenced on NovaSeq 6000. Sequencing data were analysed using Searchlight2. Read counts of HC, lesional and uninvolved skin from patients with psoriasis without PsA obtained by Tsoi et al 2019 [2](GEO accession GSE121212) were analysed using Searchlight2. Results from the two analyses were compared. Read counts of patients with PsA from the Tsoi cohort were used for validation.

Results: The PsA cohort had 9 participants and the psoriasis cohort 16 participants in each group. The Tsoi PsA cohort had 4 participants. Both PsA skin lesions (PsA L) and psoriasis skin lesions (PsO L) formed distinct populations in the respective principal component analysis plot. While the HC and PsA uninvolved skin (PsA U) populations were mixed, the psoriasis uninvolved skin (PsO U) population was skewed from the HC population toward the PsO L population. Consistent with this, there were 15 differentially expressed genes between the PsA U and HC groups, and 124 differentially expressed genes between the PsO U and HC groups. All but one overlapped with genes differentially expressed in PsO L versus HC and pathway analysis showed enrichment of pathways also enriched in PsO L.

In lesional skin, most enriched pathways were shared between PsA L and PsO L. However, PsA L skin was enriched in immunoglobulin genes while PsO L skin was not. Increased expression of immunoglobulin genes was also seen in PsA L skin in the Tsoi cohort.

Conclusion: This study found differences in the transcriptomes of psoriasis and PsA skin. PsA U skin is closer to healthy skin than PsO U skin, which shares some transcriptomic changes with PsO L skin. Although PsA L and PsO L skin share many inflammatory pathways, transcriptomic changes suggest differences in immunoglobulin pathways.

1. Cretu, D., et al., Clin Proteomics, 2015. 12(1): p. 1.
2. Tsoi, L.C., et al., J Invest Dermatol, 2019. 139(7): p. 1480-1489.


Disclosures: H. Johnsson, Eli Lilly, 12, Attendance at course and conference; J. Cole, None; S. Siebert, AbbVie, 5, 6, Biogen, 6, Amgen (previously Celgene), 5, 6, Bristol Myers Squibb, 5, Boehringer-Ingelheim, 5, Novartis, 5, 6, UCB, 5, 6, Janssen, 1, 5, 6, GlaxoSmithKline, 5; I. McInnes, Bristol Myers Squibb, 2, 5, Celgene, 2, 5, Eli Lilly, 2, 5, Janssen, 2, 5, Novartis, 2, 5, UCB, 2, 5, Gilead, 2, AbbVie, 2, AstraZeneca, 5, Boehringer Ingelheim, 2, Amgen, 2, 5, 6, Pfizer, 2, 5, 6; G. Graham, None.

To cite this abstract in AMA style:

Johnsson H, Cole J, Siebert S, McInnes I, Graham G. Psoriatic Arthritis Skin Is Transcriptionally Different to Psoriasis Skin and Enriched in Immunoglobulin Transcripts [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/psoriatic-arthritis-skin-is-transcriptionally-different-to-psoriasis-skin-and-enriched-in-immunoglobulin-transcripts/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/psoriatic-arthritis-skin-is-transcriptionally-different-to-psoriasis-skin-and-enriched-in-immunoglobulin-transcripts/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology